GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Current Deferred Revenue

3D Medicines (HKSE:01244) Current Deferred Revenue : HK$0.0 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

3D Medicines's current deferred revenue for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

3D Medicines Current Deferred Revenue Historical Data

The historical data trend for 3D Medicines's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Current Deferred Revenue Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - -

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

3D Medicines Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Current Deferred Revenue
Comparable Companies
HKSE:02616 HKSE:01873 HKSE:06622 HKSE:01167 HKSE:06978 HKSE:02496 HKSE:01672 HKSE:02181 HKSE:02256 HKSE:02137 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
Website
https://www.3d-medicines.com
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines Headlines

No Headlines